ChromaDex (CDXC) 10-Q2017 Q1 Quarterly report

Filed: 11 May 17, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Good

New words: absent, absorbed, accelerate, acid, add, adenine, aging, Allen, anniversary, answer, anthocyanin, AnthOrigin, antioxidant, appointed, appointment, approach, Asia, assessment, asset, assist, beneficial, biological, blocking, blood, botanical, bottle, Brazil, Brenner, built, caffeine, Canada, cancellation, cardiovascular, case, Cell, cellular, Central, chain, chance, clarity, Cockayne, cognitive, Committee, complaint, component, comprehensive, concentrate, concentrated, concept, Condensed, consideration, convert, conveyed, Corn, Cornell, corrective, counterclaim, covenant, create, created, creating, creative, CS, dark, database, dealing, death, decide, dedicate, degeneration, depletion, differentiation, dinucleotide, disability, disadvantage, discovery, disease, disposal, dispose, District, dollar, Dongmyung, dose, Dr, driven, DTC, dysfunction, Echinacea, elaborate, eligible, email, energy, entitled, entry, ethnobotanical, ethnopharmacological, Europe, eventually, exceeded, exemption, expert, expertise, expose, exposed, extract, extraction, faith, false, Fast, fatty, filled, flexibility, FlowsFor, foot, foreclose, Fortune, fraud, fraudulently, fundamental, gap, ginseng, glucose, GMP, goal, gram, grounded, healthy, hearing, Heathspan, heavily, heavy, hurt, identification, iii, immulina, immune, implied, importantly, imposed, Incentive, IND, indirect, induce, induced, Inside, insufficient, intensify, intent, internet, investigate, investigational, Irvine, ISO, iv, Japan, Jeffrey, JMC, jointly, kilogram, Korea, layer, Letter, leveraged, literature, macroeconomic, main, maliciously, measured, Measurement, member, membership, merge, metabolism, methodology, milk, mislabeled, misuse, mitochondria, mitochondrial, Modification, monitor, monitoring, motion, mouse, multiple, muscle, NAD, neuropathy, newly, NIA, niche, NIH, Nominating, NR, Objection, objective, observed, opened, opportunity, optimization, orphan, outcome, oxidation, oxidative, panel, penetrate, percent, peripheral, pertaining, Phase, pigment, pipeline, polyphenol, potency, potent, powerful, precursor, predominant, President, pressure, prevailing, primary, prominent, promise, promising, proof, proportionately, prorated, protocol, proven, pterostilbene, punitive, PURENERGY, Purple, put, quickly, rare, ready, realizable, realized, recruit, referencing, refinance, reinforce, release, requisite, rescission, rescuing, reserve, residual, resistance, restitution, restoring, restructure, restructuring, Robert, routine, Rx, sacrificing, salary, screening, scrutiny, seal, serve, shown, Silliker, slightly, slowly, solicited, South, speed, spirulina, square, standalone, standardization, statistically, stream, strong, study, submission, subsidiary, suite, Suntava, Syndrome, telemarketing, television, therapeutic, thereunder, toll, Topic, toxicology, trace, Track, tranche, transferred, treated, trial, ultimate, ultimately, uncollectible, unfair, unlawful, unpaid, unregistered, unsuccessful, unvested, USA, vacant, variable, vehicle, verification, Verified, verify, vest, vesting, vi, vigorously, violated, violating, virtue, vulnerable, Wako, website, willfully, winning

Removed: adjusted, array, assigned, automatically, breach, capability, charge, competitively, coupled, cumulative, director, earliest, effected, escalate, exclusivity, explore, extend, finance, fractional, fulfill, group, hand, identical, invest, medium, pilot, presented, redeemed, repayable, resale, retrospectively, reverse, Rob, round, shipped, SPA, space, Spherix, split, unanimously, unit, warrant

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

CDXC similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

Certification Pursuant to 18 U.S.C. Section 1350

(as adopted pursuant to Section 906 of the Sarbanes−Oxley Act of 2002)

In connection with this Quarterly Report of ChromaDex Corporation (the “Company”) on Form 10−Q for the quarter ended April 1, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Frank L. Jaksch, Jr., Chief Executive Officer of the Company, and Thomas C. Varvaro, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Section 906 of the Sarbanes−Oxley Act of 2002, that, to our knowledge:

1. The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 11, 2017

/s/ FRANK L. JAKSCH, JR.

Frank L. Jaksch, Jr.

Chief Executive Officer

/s/ THOMAS C. VARVARO

Thomas C. Varvaro

Chief Financial Officer

The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.